Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TX103 |
Trade Name | |
Synonyms | TX 103|TX-103 |
Drug Descriptions |
TX103 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3), which potentially enhances antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2062)). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
TX103 | TX103 | 0 | 1 |